Plunge In Valeant Pharmaceuticals Costs Top Five Shareholders, Including Ackman, Roughly $4bn |
| October 22, 2015 | October 2015 Bond Updates |
|
Some of the world's most prominent hedge fund and mutual fund investors are being punished by a relentless slide in the specialty pharmaceutical company as lawmakers and federal prosecutors investigate its pricing practices, and short sellers pore into the Quebec-based company's murky finances. |
| View more at: http://www.forbes.com/sites/antoinegara/2015/10/21/valeants-slide-costs-top-five-shareholders-including-bill-ackman-roughly-4-billion/ |
| Related News |